This is a preview of subscription content, log in via an institution to check access.
Notes
PCSK9 Inhibitor Therapies for High Cholesterol: Effectiveness, Value, and Value-Based Price Benchmarks
CardioMEMS™ HF System (St. Jude Medical) and Sacubitril/Valsartan (Entresto™, Novartis) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks.
a system for monitoring increases in pulmonary artery pressure, a key indicator of worsening heart failure
References
Institute for Clinical and Economic Review. ICER Draft Report on Effectiveness, Value, and Pricing Benchmarks for PCSK9 Inhibitors for High Cholesterol Posted for Public Comment . Internet Document : 8 Sep 2015. Available from: URL: http://www.icer-review.org/pcsk9-draft-report-release/.
Institute for Clinical and Economic Review. ICER Draft Report on CardioMEMS and Entresto for Management of Congestive Heart Failure Posted for Public Comment . Internet Document : 11 Sep 2015. Available from: URL: http://www.icer-review.org/chf-draft-report-posted/.
National Pharmaceutical Council. Value Is in the Eye of the Beholder? NPC Takes Closer Look at ICER Framework. Internet Document : 15 Sep 2015. Available from: URL: http://www.npcnow.org/icer-webinar-statement.
Rights and permissions
About this article
Cite this article
ICER releases first reports, while its framework is analysed. PharmacoEcon Outcomes News 737, 2 (2015). https://doi.org/10.1007/s40274-015-2448-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2448-4